Skip to main content

The common enemy of Parkinson's, prostate cancer and Alzheimer's

18 Aug 16




Press and Communications Officer
Tel.+34 93 40 37255

El Heraldo de Aragon and other media have echoed the research headed by Xavier Salvatella, group leader of the Laboratory of Molecular Biophysics at IRB Barcelona. The study, published in ACS Chemical Biology found—contrary to what was believed until now—that disordered regions of proteins can be used as therapeutic targets and that they may have applications on Alzheimer's, Parkinson's and prostate cancer.

About IRB Barcelona

Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 27 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).